Article
Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Molecular medicine (Cambridge, Mass.) - 1 Aug 2002
Kawakami Koji, Husain Syed R, Kawakami Mariko, Puri Raj K
Abstract excerpt
BACKGROUND: IL-13 receptor (IL-13R) targeted cytotoxin, IL13-PE38QQR, has been shown to have very potent anti-tumor activity to IL-13R-expressing head and neck tumor cells in vitro and in vivo. However, its effect is limited in aggressive tumors. To further improve the anti-tumor activity and safety of IL-13 cytotoxin, we employed continuous infusion technique in animal model of head and neck cancer. MATERIALS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.